Relief Therapeutics Holdings AG
Shares being used in part for payments related to AdVita and APR acquisitions
Acquisitions are part of Relief's transformation into a fully integrated diversified commercial-stage pharmaceutical company
GENEVA, SWITZERLAND / ACCESSWIRE / July 22, 2021 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) ("Relief" or the "Company"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the Company will, on or around July 27, 2021, issue 1,000,000,000 additional registered shares out of the authorized share capital approved by the Annual General Meeting on June 18, 2021. The new shares are fully subscribed at par value by the Company's wholly owned subsidiary, Relief Therapeutics International SA, and will be listed on the SIX Swiss Exchange on or around July 28, 2021. Some of the shares will be used for contractually agreed payments to the respective sellers of AdVita Lifescience GmbH ("AdVita") and APR Applied Pharma Research SA ("APR"): approximately 140,000,000[1] shares and 206,786,784 shares, respectively. The remaining new shares will be held as treasury shares for possible future financing transactions, acquisitions, general corporate purposes, and the settlement of possible future contingent milestone payments to the APR and AdVita sellers. The APR sellers are generally subject to a 75-day lock-up period and a subsequent leak-out schedule.
Jack Weinstein, CFO and Treasurer of Relief, said: "During the course of 2021, we have taken several important steps to transform Relief into a multi-product, revenue-generating company. One critical component of that was the recently closed acquisition of APR, which brings us a diverse pipeline, including market-stage products, and provides a commercial springboard for future Relief product launches. We also are strengthening our intellectual property position with our lead candidate, RLF-100(TM) (aviptadil), through the planned acquisition of AdVita. We are also actively continuing to look for other opportunities as we build our business."
The associated listing prospectus will be listed on the SIX Prospectus Office's website and will be made available upon request once it has been approved by the SIX Swiss Exchange, which is expected on or around July 27, 2021.
###
ABOUT RELIEF
Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief's lead drug candidate, RLF-100TM (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease. In addition, Relief's acquisition of APR Applied Pharma Research brings a diverse pipeline of marketed and development-stage programs.
RELIEF THERAPEUTICS Holding AG is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. For more information, visit www.relieftherapeutics.com. Follow us on LinkedIn.
CONTACT:
RELIEF THERAPEUTICS Holding AG
Jack Weinstein
Chief Financial Officer and Treasurer
Mail: contact@relieftherapeutics.com
FOR MEDIA/INVESTOR INQUIRIES:
MC Services AG
Anne Hennecke
Tel.: +49 (0) 211-529-252-22
Mail: relief@mc-services.eu
Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
[1] The exact figure is i.a. dependent on Relief's closing share price on the SIX trading day preceding the closing date of Relief's acquisition of AdVita's outstanding shares.
SOURCE: Relief Therapeutics Holdings AG
To view this piece of content from eqs-cockpit.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/656612/Relief-Announces-Issuance-of-Shares-from-Authorized-Capital-as-Approved-by-2021-Annual-General-Meeting
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Sauce Labs Achieves Milestone Fifth Consecutive ISO 27001 Certification, Reinforcing World-Class Security and Privacy Commitment20.1.2026 09:00:00 CET | Press release
SAN FRANCISCO, CA / ACCESS Newswire / January 20, 2026 / Sauce Labs, the leading provider of Continuous Testing and Cloud-based Software Quality solutions, today announced the successful renewal of its critical ISO/IEC 27001:2022 and ISO 27701:2019 certifications. This achievement marks the fifth consecutive year for the ISO/IEC 27001 (Information Security Management System) and the fourth consecutive year for the ISO 27701 (Privacy Information Management System), solidifying the company's position as a trusted partner for global enterprises. The rigorous, independent audit confirmed Sauce Labs' systematic and robust approach to managing sensitive information and personal data, resulting in zero Minor or Major Nonconformities. "Reaching this five-year milestone with zero nonconformities is a massive validation of our ongoing investment in security and compliance," said Marcia Foley, VP of Global Compliance at Sauce Labs. "For our customers, this renewal is undeniable proof that Sauce L
IXOPAY Launches New TokenEx Packages, Setting the Standard for Token-First Payments in the Era of Agentic Commerce20.1.2026 06:00:00 CET | Press release
New TokenEx packages give merchants a faster, clearer path to secure and independent payments. In parallel, IXOPAY expands its global payments capabilities with new support for Brazil's PIX instant payment system. LEHI, UTAH / ACCESS Newswire / January 20, 2026 / IXOPAY, the enterprise-grade global payment infrastructure platform built for the era of agentic commerce, today announced the launch of three new TokenEx tokenization packages designed to help merchants secure payment data, reduce complexity, and maintain independence across processors, markets, and payment methods. As payments ecosystems become increasingly fragmented, many businesses remain constrained by processor-owned tokens, rigid integrations, and infrastructure that is costly to change. IXOPAY's new TokenEx packages establish tokenization as the foundation for modern payments, giving merchants a standardized, future-ready way to protect data, retain control, and scale without re-architecting their payments stack. "Tok
RE Royalties Announces Annual Grant of Stock Options and Restricted Share Units20.1.2026 00:00:00 CET | Press release
All amounts in Canadian dollars unless otherwise stated VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / RE Royalties Ltd. (TSXV:RE)(OTCQX:RROYF)(FSE:Y2V) ("RE Royalties" or the "Company") is pleased to announce that, as part of the Company's annual compensation review, the Board of Directors have authorized the grant of 1,195,000 stock options (the "Options") to directors, officers, employees and consultants of the Company. The Options have an exercise price of CAD $0.30 per share and are exercisable for a period of three-years from the date of grant. The Options were granted in accordance with the Company's Stock Option Plan. In addition, the Board of Directors have authorized the grant of an aggregate 800,000 restricted share units ("RSUs") to officers, employees and consultants of the Company. The RSUs were granted in accordance with the Company's RSU Plan in place. "We are pleased to provide these incentive-based equity awards to our valued team members," said Bernard Tan, CEO
GA-ASI and Barzan Holdings Sign MOU19.1.2026 18:00:00 CET | Press release
Companies Will Collaborate on the Development of Advanced Battle Management DOHA, QA / ACCESS Newswire / January 19, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) -- the world leader in unmanned systems - and Barzan Holdings, Qatar's national defence and security leader, signed a Memorandum of Understanding (MOU) to collaborate on the development of advanced Battle Management software capabilities. The signing took place on Monday during the Doha International Maritime Defence Exhibition and Conference (DIMDEX). The MOU provides a framework for cooperation between GA-ASI, GA-Intelligence, and Barzan Holdings to develop software solutions that enhance theater-level situational awareness and enable the efficient processing, correlation, and dissemination of intelligence. These capabilities are intended to support faster, higher-quality decision-making in complex, multi-domain operational environments. For General Atomics, the agreement underscores the strategic importance of
GA-ASI Makes Another Autonomous Aerial Intercept in Company-Funded Demo with MQ-20 Avenger(R)19.1.2026 03:00:00 CET | Press release
SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 18, 2026 / In its latest demonstration of advanced autonomy development, General Atomics Aeronautical Systems, Inc. (GA-ASI) successfully executed a mission autonomy flight using its MQ-20 Avenger® jet equipped with the latest government reference autonomy software. The test included a live engagement between the MQ-20 and an aggressor aircraft flown by an onboard human pilot, highlighting the advanced maturity of autonomous systems, seamless integration of mission elements, and the ability of autonomy to leverage onboard sensors to make independent decisions and execute complex tasks. GA-ASI's Avenger jet has served as a surrogate for Collaborative Combat Aircraft (CCA) for more than five years, both before and since the arrival of GA-ASI's purpose-built XQ-67A and YFQ-42A aircraft. The recent Avenger demo began with planning in the Human-Machine Interface (HMI), followed by loading the mission profile onto the MQ-20. Once airborne, th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom